Literature DB >> 24253104

Harnessing local and systemic immunity for vaccines against tuberculosis.

P C L Beverley1, S Sridhar2, A Lalvani2, E Z Tchilian1.   

Abstract

The lung is the portal of entry for Mycobacterium tuberculosis (Mtb) and animal experimental evidence indicates that local immune defense mechanisms are crucial for protective immunity. Immunization via the lower respiratory tract efficiently induces a dividing, activated, antigen-dependent, lung-resident, memory T-cell population, which is partly recoverable by bronchoalveolar lavage. These cells can inhibit the growth of Mtb in the lungs immediately after infection. Delivery of appropriate signals to the lung innate immune system is critical for induction of effective local immunity. In contrast after parenteral immunization, antigen-specific cells may be found in lung tissue but few are recoverable by lavage and inhibition of mycobacterial growth is delayed. Harnessing both local and systemic immunity can provide highly effective protection in animal models and the evidence suggests that taken in aggregate, multiple animal models may predict the success of novel vaccine strategies in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24253104     DOI: 10.1038/mi.2013.99

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  84 in total

1.  Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing.

Authors:  S A Sharpe; H McShane; M J Dennis; R J Basaraba; F Gleeson; G Hall; A McIntyre; K Gooch; S Clark; N E R Beveridge; E Nuth; A White; A Marriott; S Dowall; A V S Hill; A Williams; P D Marsh
Journal:  Clin Vaccine Immunol       Date:  2010-06-09

2.  Airborne immunization against tuberculosis.

Authors:  M L COHN; C L DAVIS; G MIDDLEBROOK
Journal:  Science       Date:  1958-11-21       Impact factor: 47.728

3.  Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing.

Authors:  Nia Tatsis; Shih-Wen Lin; Kimberly Harris-McCoy; David A Garber; Mark B Feinberg; Hildegund C J Ertl
Journal:  Virology       Date:  2007-06-27       Impact factor: 3.616

4.  ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes.

Authors:  William W Reiley; Mark D Calayag; Susan T Wittmer; Jennifer L Huntington; John E Pearl; Jeffrey J Fountain; Cynthia A Martino; Alan D Roberts; Andrea M Cooper; Gary M Winslow; David L Woodland
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

5.  Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice.

Authors:  Elihu Aranday Cortes; Daryan Kaveh; Javier Nunez-Garcia; Philip J Hogarth; H Martin Vordermeier
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

6.  Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.

Authors:  Scott G Hansen; Jonah B Sacha; Colette M Hughes; Julia C Ford; Benjamin J Burwitz; Isabel Scholz; Roxanne M Gilbride; Matthew S Lewis; Awbrey N Gilliam; Abigail B Ventura; Daniel Malouli; Guangwu Xu; Rebecca Richards; Nathan Whizin; Jason S Reed; Katherine B Hammond; Miranda Fischer; John M Turner; Alfred W Legasse; Michael K Axthelm; Paul T Edlefsen; Jay A Nelson; Jeffrey D Lifson; Klaus Früh; Louis J Picker
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

Review 7.  Cell-mediated immune responses in tuberculosis.

Authors:  Andrea M Cooper
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

8.  Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway.

Authors:  Julius A Potian; Wasiulla Rafi; Kamlesh Bhatt; Amanda McBride; William C Gause; Padmini Salgame
Journal:  J Exp Med       Date:  2011-08-08       Impact factor: 14.307

9.  MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.

Authors:  Frank A W Verreck; Richard A W Vervenne; Ivanela Kondova; Klaas W van Kralingen; Edmond J Remarque; Gerco Braskamp; Nicole M van der Werff; Ariena Kersbergen; Tom H M Ottenhoff; Peter J Heidt; Sarah C Gilbert; Brigitte Gicquel; Adrian V S Hill; Carlos Martin; Helen McShane; Alan W Thomas
Journal:  PLoS One       Date:  2009-04-15       Impact factor: 3.240

10.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

Authors:  Michele D Tameris; Mark Hatherill; Bernard S Landry; Thomas J Scriba; Margaret Ann Snowden; Stephen Lockhart; Jacqueline E Shea; J Bruce McClain; Gregory D Hussey; Willem A Hanekom; Hassan Mahomed; Helen McShane
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321

View more
  36 in total

1.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

Review 2.  Th1 cytokines, true functional signatures for protective immunity against TB?

Authors:  Gucheng Zeng; Guoliang Zhang; Xinchun Chen
Journal:  Cell Mol Immunol       Date:  2017-11-20       Impact factor: 11.530

3.  Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine.

Authors:  Yushi Yao; Rocky Lai; Sam Afkhami; Siamak Haddadi; Anna Zganiacz; Fatemeh Vahedi; Ali A Ashkar; Charu Kaushic; Mangalakumari Jeyanathan; Zhou Xing
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

4.  Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation.

Authors:  Sam Afkhami; Rocky Lai; Michael R D'agostino; Maryam Vaseghi-Shanjani; Anna Zganiacz; Yushi Yao; Mangalakumari Jeyanathan; Zhou Xing
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

Review 5.  Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis.

Authors:  Kevin B Urdahl
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

6.  Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.

Authors:  Yiling Zhang; Liqiang Feng; Liang Li; Dimin Wang; Chufang Li; Caijun Sun; Pingchao Li; Xuehua Zheng; Yichu Liu; Wei Yang; Xuefeng Niu; Nanshan Zhong; Ling Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Diversity of Human and Macaque Airway Immune Cells at Baseline and during Tuberculosis Infection.

Authors:  Richard F Silver; Amy J Myers; Jessica Jarvela; JoAnne Flynn; Tara Rutledge; Tracey Bonfield; Philana Ling Lin
Journal:  Am J Respir Cell Mol Biol       Date:  2016-12       Impact factor: 6.914

8.  Mucosal delivery of ESX-1-expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes.

Authors:  Harindra D Sathkumara; Visai Muruganandah; Martha M Cooper; Matt A Field; Md Abdul Alim; Roland Brosch; Natkunam Ketheesan; Brenda Govan; Catherine M Rush; Lars Henning; Andreas Kupz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-10       Impact factor: 11.205

Review 9.  Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.

Authors:  McKayla J Nicol; David R Williamson; David E Place; Girish S Kirimanjeswara
Journal:  Microorganisms       Date:  2021-04-30

Review 10.  Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool.

Authors:  Christopher L Karp; Christopher B Wilson; Lynda M Stuart
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.